© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
Digital Screening Tool Duo Shows Promise for ADRD Detection in Primary Care
November 12, 2025
Indiana University study found that integrating patient-reported outcome questionnaires with machine learning boosts dementia diagnoses by 31% in primary care settings.
Large-Scale Study Challenges Previous Research on Menopause and Brain Structure
November 11, 2025
TMS 2025: Katrina Wugalter, MA, discusses research showing that age—not menopause stage—drives brain volume decline, and how lifestyle factors can help preserve brain health in midlife women.
Mayo Clinic Researcher on Why Menopause Stage Matters in Metabolic Research
November 11, 2025
TMS 2025: Regina Castaneda, MD, explains why reproductive stage is a critical variable in obesity and metabolic research.
Tapinarof Cream 1%, Shows Early and Durable Response in Children With Atopic Dermatitis
November 11, 2025
ACAAI 2025. Phase 3 data show tapinarof cream provides early, sustained improvement and good tolerability in children aged ≥2 years with atopic dermatitis.
Vitamin D Dosing Tailored to Optimal Levels Reduced Risk of Recurrent MI by More Than Half
November 11, 2025
The TARGET-D trial found targeted vitamin D dosing post-MI didn’t lower MACE but reduced recurrent MI risk, supporting individualized serum-level management.
Sublingual Epinephrine Film Well Tolerated in Children, Matches Efficacy Seen in Adults
November 10, 2025
Sublingual epinephrine film matches adult PK/PD in kids aged 7-17 with a history of allergic reactions and high risk for serious allergic reactions, incluing anaphylaxis.
FDA to Remove “Black Box” Warnings from Hormone Replacement Therapy Products
November 10, 2025
Regulatory update aims to align labeling with current evidence on menopausal hormone therapy safety and benefits
Investigational Oral PCSK-9 Inhibitor Reduces LDL-C by 60% in Late Stage HeFH Trial
November 10, 2025
Merck's oral PCSK9 inhibitor enlicitide demonstrated antibody-like LDL-C lowering in adutls with HeFH with safety profile similar to placebo in phase 3 trial.
Primary Care Training Drives Higher Adoption and Continued Use of LARC Methods: Daily Dose
November 10, 2025
Your daily dose of the clinical news you may have missed.
Treg-Targeting Rezpegaldesleukin Demonstrates Dual Benefit for Asthma and Atopic Dermatitis
November 10, 2025
Phase 2b findings show rezpegaldesleukin reduced ACQ-5 scores and improved key AD endpoints in participants with comorbid asthma.